CClinicalTrials.gg
Sign In
CompletedNCT04245241Updated Jan 28, 2020

Effects of High-Flow Nasal Cannula Therapy Assessed by Electrical Impedance Tomography

An observational study in High-flow Nasal Cannula and Electrical Impedance Tomography, sponsored by Peking Union Medical College Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Peking Union Medical College Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
24
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study aimed to determine the effects of HFNC therapy on lung recruitment and lung strain change assessed by electrical impedance tomography (EIT)

02

Conditions studied

  • High-flow Nasal Cannula
  • Electrical Impedance Tomography
03

In context

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

adult critically ill patients, who received a HENC therapy within 24 h after the extubation, were enrolled.

Inclusion criteria

  • Patient who received a HENC therapy within 24 h after the extubation

Exclusion criteria

Exclusion Criteria:

  • Aged \<18 years
  • Pregnancy
  • Body mass index (BMI) over 50 kg/m2
  • ribcage malformation .any contraindication of using EIT monitoring (automatic implantable cardioverter defibrillator, chest skin injury, etc.).
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No

Interventions

  • OtherHigh-flow nasal cannula (HFNC)

    24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).

06

What researchers measure

Primary outcomes

  1. lung regional ventilation distribution

    lung regional ventilation distribution measured by EIT

    Time frame: minute 80

07

Study locations

1 site
  • Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,
    Beijing, Beijing 100730, China
08

References and documents

Publications

  • Zhang R, He H, Yun L, Zhou X, Wang X, Chi Y, Yuan S, Zhao Z. Effect of postextubation high-flow nasal cannula therapy on lung recruitment and overdistension in high-risk patient. Crit Care. 2020 Mar 6;24(1):82. doi: 10.1186/s13054-020-2809-7. PubMed 32143664 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04245241
Lead sponsor
Peking Union Medical College Hospital
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
May 1, 2018
Primary completion
Jul 1, 2019
Completion
Nov 1, 2019
Last update
Jan 28, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Peking Union Medical College Hospital

Start the discussion